Abstract

Toxoplasma gondii encephalitis occurs in up to 30% of HIV-infected individuals with latent infection. Anti-toxoplasma chemotherapy is often toxic, and despite adequate therapy, disease recurs in up to 50% of patients with AIDS. An understanding of the cellular immune response to T. gondii infection may aid in the development of improved predictors of the risk for recrudescent disease, and may lead to effective immunotherapies. We have constructed recombinant vaccinia viruses that express the 28-kD toxoplasma antigen. A second vector that expresses the p22 antigen of T. gondii is currently being constructed in our laboratory. By using these vectors to induce autologous EBV-transformed lymphoblasts to express toxoplasma antigens, we can examine cytotoxic T-cell activity of cells derived from individuals with a history of T. gondii infection. We propose to study toxoplasma-specific CTL responses of T. gondii-seropositive, HIV- infected individuals.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
2U01AI032770-05
Application #
5205506
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
1996
Total Cost
Indirect Cost

  Publications

Winham, Stacey J; Slater, Andrew J; Motsinger-Reif, Alison A (2010) A comparison of internal validation techniques for multifactor dimensionality reduction. BMC Bioinformatics 11:394
Williams, Pl; Wu, Jw; Cohn, Se et al. (2009) Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution. HIV Med 10:290-301
Skowron, Gail; Spritzler, John G; Weidler, Jodi et al. (2009) Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects. J Acquir Immune Defic Syndr 50:250-8
Gerber, John G; Kitch, Douglas W; Fichtenbaum, Carl J et al. (2008) Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr 47:459-66
Sattler, Fred R; Rajicic, Natasa; Mulligan, Kathleen et al. (2008) Evaluation of high-protein supplementation in weight-stable HIV-positive subjects with a history of weight loss: a randomized, double-blind, multicenter trial. Am J Clin Nutr 88:1313-21
Ma, Qing; Forrest, Alan; Rosenkranz, Susan L et al. (2008) Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers. Biopharm Drug Dispos 29:91-101
Rosenkranz, Susan L; Yarasheski, Kevin E; Para, Michael F et al. (2007) Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic Analysis. Metab Syndr Relat Disord 5:163-73
Riddler, Sharon A; Jiang, Hongyu; Tenorio, Allan et al. (2007) A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antivir Ther 12:531-41
Margolis, David M; Mukherjee, A Lisa; Fletcher, Courtney V et al. (2007) The use of beta-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection. AIDS 21:2025-32
Fischl, Margaret A; Collier, Ann C; Mukherjee, A Lisa et al. (2007) Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen. AIDS 21:325-33

Showing the most recent 10 out of 55 publications